Galenika's privatisation is suspended in Serbia

Serbia's national privatisation agency has announced that it is no longer selling its 70% stake in Galenika, the country's largest pharmaceutical manufacturer, and that no tenders will be organised this year. It said that no bidders could meet the requirements it had outlined.

Serbia's national privatisation agency has announced that it is no longer selling its 70% stake in Galenika, the country's largest pharmaceutical manufacturer, and that no tenders will be organised this year. It said that no bidders could meet the requirements it had outlined.

The agency issued its latest invitation to bid for the stake last December, hoping to raise at least €200 million,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.